Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded ...

AstraZeneca has begun working with Schrödinger to incorporate its machine learning and molecule-modeling platform within its drug discovery work, soon after the computing company received a ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, and two City University of New York ...

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced an ...